Bioequivalence and pharmacokinetic evaluation of two formulations of glimepiride 2 mg: A single-dose, randomized-sequence, open-label, two-way crossover study in healthy chinese male volunteers

Clinical Therapeutics

Volumn 32, Issue 5, 2010, Pages 986-995

  Liu, Yun ^a   Zhang, Meng qi ^a   Zhu, Jian min ^a   Jia, Jing ying ^a   Liu, Yan mei ^a   Liu, Gang yi ^a   Li, Shuijun ^a   Weng, Li ping ^a   Yu, Chen ^a  

^a SHANGHAI XUHUI CENTRAL HOSPITAL   (China)

Author keywords

Bioequivalence; Glimepiride; LC MS MS; Liquid chromatography tandem mass spectrometry; Pharmacokinetics

Indexed keywords

DRUG METABOLITE; GENERIC DRUG; GLIMEPIRIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEATH; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ERYTHROCYTE; EVALUATION; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN EXPERIMENT; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INCIDENCE; LABORATORY TEST; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; VITAL SIGN;

ADOLESCENT; ADULT; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CHINA; CROSS-OVER STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; SULFONYLUREA COMPOUNDS; THERAPEUTIC EQUIVALENCY;

EID: 77954763720     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.04.016     Document Type: Article

References (24)

1. Müller G, Satoh Y, Geisen K Extrapancreatic effects of sulfonylureas-a comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract. 1995, 28(Suppl):S115-S137.
2. Rosskamp R, Wernicke-Panten K, Draeger E Clinical profile of the novel sulphonylurea glimepiride. Diabetes Res Clin Pract. 1996, 31(Suppl):S33-S42.
3. Campbell RK Glimepiride: Role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother. 1998, 32:1044-1052.
4. Massi-Benedetti M Glimepiride in type 2 diabetes mellitus: A review of the worldwide therapeutic experience. Clin Ther. 2003, 25:799-816.
5. Amaryl (glimepiride tablets) 2009, Sanofi-Aventis US LLC, Bridgewater, NJ, Accessed September 20, 2009. http://products.sanofi-aventis.us/amaryl/amaryl.pdf.
6. Malerczyk V, Badian M, Korn A, et al. Dose linearity assessment of glimepiride (Amaryl) tablets in healthy volunteers. DrugMetabol Drug Interact. 1994, 11:341-357.
7. Rosenkranz B Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients. Horm Metab Res. 1996, 28:434-439.
8. Suzuki K, Yanagawa T, Shibasaki T, et al. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmaco-kinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract. 2006, 72:148-154.
9. Wang R, Chen K, Wen SY, et al. Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms. Clin Pharmacol Ther. 2005, 78:90-92.
10. Badian M, Korn A, Lehr KH, et al. Pharmacokinetics and pharmacodynamics of the hydroxymetabolite of glimepiride (Amaryl) after intravenous administration. Drug Metabol Drug Interact. 1996, 13:69-85.
11. Borges NC, Taveira Ydel A, Mazucheli JA, et al. Comparison study of two glimepiride formulations bioavailability in healthy volunteers of both sexes after a single dose administration [in Portuguese]. Arq Bras Endocrinol Metabol. 2007, 51:950-955.
12. Matsuki M, Matsuda M, Kohara K, et al. Pharmacokinet-ics and pharmacodynamics of glimepiride in type 2 diabetic patients: Compared effects of once- versus twice-daily dosing. Endocr J. 2007, 54:571-576.
13. Lei T, Yi-ling H, Lu H, et al. Pharmacokinetic studies of glimepiride and its hydroxyl-metabolite in healthy volunteers. Chin J Clin Pharmacol Ther. 2006, 11:868-972.
14. Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 52nd WMA General Assembly October 7, 2000, World Medical Association (WMA) Declaration of Helsinki, Accessed September 20, 2007. http://www.wma.net/en/30publications/10policies/b3/index.html.
15. International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice. ICH topic E 6 (R1) European Agency for the Evaluation of Medicinal Products (EMEA), Accessed December 1, 2009. http://www.ema.europa.eu/pdfs/human/ich/013595en.pdf.
16. Guideline for Good Clinical Practice [in Chinese] State Food and Drug Administration, Accessed December 1, 2009. http://www.sda.gov.cn/WS01/CL0053/24473.html.
17. Guidance on Glimepiride. Finalized May 2008, US Food and Drug Administration (FDA), Accessed December 1, 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM086202.pdf.
18. Salem II, Idrees J, Al Tamimi JI Determination of glimepiride in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004, 799:103-109.
19. Shumaker RC PKCALC: A BASIC interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab Rev. 1986, 17:331-348.
20. Guideline for bioavailability and bioequivalence studies of generic drug products [in Chinese] State Food and Drug Administration, Center for Drug EvaluationCenter for Drug Evaluation, Accessed December 1, 2009. http://www.cde.org.cn/zdyz.do?method=largePage&id=2066.
21. Xu H, Murray M, McLachlan AJ Influence of genetic polymorphisms on the pharmacokinetics and phar-macodynamics of sulfonylurea drugs. Curr Drug Metab. 2009, 10:643.
22. Kirchheiner J, Roots I, Goldammer M, et al. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharma-cokinetics of oral antidiabetic drugs: Clinical relevance. Clin Pharmacokinet. 2005, 44:1209-1225.
23. Kim YM, Yoo SH, Kang RY, et al. Identifying drugs needing pharma-cogenetic monitoring in a Korean hospital. Am J Health Syst Pharm. 2007, 64:166-175.
24. Guidance for Industry. Bioavailability and bio-equivalence studies for orally administered drug products-general considerations US Dept of Health and Human Services, Food and Drug Administration (FDA)Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER)Center for Drug Evaluation and Research (CDER), Accessed December 1, 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070124.pdf.